Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company, announced the acquisition of a portfolio of dopamine agonist drug combinations from Chase Therapeutics Corporation. This includes ALTO-207, formerly known as CTC-501, aimed at treating treatment-resistant depression $(TRD.UK)$. The acquisition aligns with Alto's mission to innovate in psychiatry by advancing ALTO-207, which combines pramipexole and ondansetron to deliver rapid antidepressant effects while minimizing adverse events. Alto plans to leverage its proprietary insights on dopamine biomarkers to further develop this promising treatment, with a Phase 2b trial anticipated by mid-2026. The transaction supports Alto's strategic expansion without altering its cash runway guidance into 2028.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。